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Abstract 
We report the case of a 46-year-old female patient with WDHA (watery 
diarrhea/hypokalemia/achlorhydria) syndrome caused by a pancreatic 
polypeptide-producing tumor in the head of the pancreas. Whereas VIP and other 
pancreatic endocrine hormones were in the normal range, only serum levels of 
pancreatic polypeptide were elevated. Imaging studies identified a pancreatic tumor in 
the head of the gland. After laparotomy, the tumor of 3 cm in size was enucleated. Final 
pathology documented a pancreatic endocrine tumor with immunohistochemical 
staining demonstrating the presence of pancreatic polypeptide. The patient remained 
cured after a follow-up of more than three years. The present case illustrates that, 
although rare, WDHA syndrome may be associated with a pancreatic polypeptide-
secreting endocrine tumor of the pancreas. 
 
Introduction 
Endocrine tumors of the pancreas (ETPs) are rare but fascinating tumors. They occur 
in approximately 1 in 100,000 or represent 1–2% of all pancreatic neoplasms. Some of the 
tumors may be part of the multiple endocrine neoplasia type one syndrome (MEN-1). 
ETPs are categorized on the basis of their clinical manifestation into functioning and 
nonfunctioning tumors. Functioning tumors are associated with a clinical syndrome 
caused by inappropriate secretion of hormones. Within this group are insulinomas, 
glucagonomas, somatostatinomas, gastrinomas, vasoactive intestinal polypeptide 
producing tumors (VIPomas) and other less common tumors. VIPomas have been 
associated with watery diarrhea syndrome. It has also been called Verner-Morrison 
syndrome, pancreatic cholera or WDHA (watery diarrhea/hypokalemia/achlorhydria)  
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syndrome. This syndrome is characterized by secretory diarrhea which ranges between 
0.5 and 15 l/24 h and which is usually the most prominent symptom at presentation. It 
results in severe loss of potassium and bicarbonate, which in turn lead to metabolic 
acidosis and dehydration. Additional features include hypercalcemia with normal 
parathyroid hormone levels, hyperglycemia, and occasionally flushing of the face and the 
chest. The diagnosis of a VIPoma is confirmed by measurement of plasma VIP, and levels 
above 60 pmol/l are diagnostic. 
Nonfunctioning ETPs are not associated with a distinct hormonal syndrome, but may 
still show elevated hormone levels in the blood or immunoreactivity in tissue sections. 
The majority of nonfunctioning ETPs express and/or secrete pancreatic polypeptide (PP), 
which can therefore serve as a general tumor marker in ETPs. PP was discovered in 1968, 
when Kimmel and colleagues [1], while purifying chicken insulin, found a new peptide 
hormone which they named ‘pancreatic polypeptide’. The role of PP in ETPs may be 
involved in several ways. First, cases of pure PP-producing tumors, so-called PPomas; 
second, mixed ETPs containing PP cells; and third, cases of PP cell hyperplasia. Although 
PP frequently occurs in patients with ETPs, elevated serum levels of PP were not 
connected with specific clinical symptoms. 
Herein, we report only the fifth case of the world literature with a pure PPoma of the 
pancreatic head causing WDHA syndrome. 
Case Report 
A 46-year-old woman was admitted to our hospital because of a 2-year history of diarrhea. This 
watery diarrhea occurred 3–10 times daily and was painless and without blood. She reported a weight 
loss of 5–6 kg in these two years. All tests for infectious disease as well as a colonoscopy were negative. 
One month prior to admission, she had undergone CT imaging of the abdomen, which showed a 
pancreatic head tumor, 4.2 × 3.3 cm in size (fig. 1a). Her medical history revealed an appendectomy as a 
child and a benign cyst of the right breast. On admission, physical examination revealed a thin woman 
in no acute distress. No lymphadenopathy was noted. Determination of peptide hormones in the serum 
showed greatly increased concentrations of PP with 4,370 pg/ml (normal up to 80 pg/ml). Surprisingly 
serum levels of VIP were normal with 8.5 pmol/l (norm up to 36 pmol/l), the same was found for 
gastrin with levels of 12 pg/ml (norm up to 60 pg/ml). Abdominal ultrasound showed a hypoechoic 
tumor in the pancreatic head 4.8 × 3.6 × 3.2 cm in size. None of the diagnostic procedures showed any 
signs of distant metastases. 
After laparotomy the tumor was visualized by intraoperative ultrasound (fig. 1b), which showed the 
tumor next to the uncinate process. The tumor was enucleated (fig. 2a) and a pancreaticojejunostomy 
was done for closing the defect of the gland. Further exploration of the abdomen revealed no evidence 
of metastatic disease. Postoperatively the patient had to be reoperated after three days because of 
bleeding. The further postoperative course was uneventful. Her serum PP level after removal of the 
tumor was 55 pg/ml and was completely suppressed by 1 mg intravenous atropine. After a follow-up of 
three years she remained well without any watery diarrhea or any other signs of tumor recurrence. 
Histopathological Examination 
The tumor specimen showed a tumor with 3 cm (fig. 2b) in diameter, with a weight of 12 g. 
Microscopically the neoplasm was an endocrine tumor, proven by a strong expression of 
chromogranin A (fig. 2c). It had a well-defined capsule and was made up of small cuboidal to slightly 
elongated cells with round nuclei and clear to eosinophilic cytoplasm. The tumor cells were arranged in 
various patterns, a characteristic feature of islet cell tumors. These included solid, ribbon-like and 
glandular growth pattern. Results of immunohistochemical staining specific for insulin, glucagons, 
somatostatin, and gastrin were negative. However, staining for PP was positive in the main tumor mass 
(fig. 2d).  
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Discussion 
In mammals, virtually all of the PP-producing cells are located in the pancreas. They 
have been found within the islets, scattered in the exocrine compartment, and lining the 
ducts. Within the islets the PP cells are located mainly in the periphery, wedged between 
the A and B cells. PP islet cells are relatively abundant in both the murine ventral and 
dorsal pancreatic buds by day 15.5 of gestation. Subsequently, at day 18.5 of gestation, the 
total number of PP cells in the murine ventral bud has doubled, whereas the number in 
the murine dorsal bud has essentially remained unchanged [2]. This nonhomogenous 
distribution of PP cells can also be seen in the human neonate. Indeed, PP cells are more 
numerous in the uncinate process than in the body and tail and rest of the pancreatic 
head. This anatomic distribution of PP cells is also present in the adult human pancreas 
[3]. Infusions of PP in man demonstrate that, at physiological levels, it acts solely on the 
pancreas and gallbladder by inhibiting the secretion of bile and of pancreatic enzymes and 
juice [4]. Thus a tumor deriving from PP cells is predicted to be clinically silent. That is 
this not always the case as illustrated in this case and table 1. In 1979, there was still 
controversy about how often WDHA syndrome, with a causal pancreatic tumor, is 
mediated by excessive secretion of VIP [4]. Although elevated VIP serum levels were 
measured in the majority of patients, there have been reports about so-called Pseudo-
Verner-Morrison syndromes with a clinical WDHA syndrome in the presence of normal 
VIP serum levels. 
Larsson et al. were the first to report on a patient with diarrhea due to a pancreatic 
tumor in whom PP was markedly elevated in the plasma with normal levels of VIP in the 
plasma [5]. In 1980 Hayes presented a case of a PP-producing islet cell tumor causing 
WDHA [6]. Unfortunately there are no more data like VIP serum levels of this case 
available. Four years later, Strodel et al. published a series of eight patients with 
PP-producing islet cell tumors [7]. Two patients presented with diarrhea, but in only one 
of them a pancreatic tumor was found and resected. The last report came from 
Mortenson and Bold [8]. They described a 64-year-old woman who presented with 
watery diarrhea in the presence of MEN-1 syndrome. Of various potential pancreatic 
endocrine hormones, only serum levels of PP were elevated. Radiologic imaging failed to 
identify a pancreatic tumor; her diarrhea was therefore managed with subcutaneous 
administration of somatostatin. Three years later she developed gallstone pancreatitis 
with the subsequent development of a pancreatic pseudocyst. At exploration for drainage 
of the pseudocyst, intraoperative ultrasound identified a 6-mm tumor in the distal 
pancreas that was resected. Final pathology documented a pancreatic endocrine tumor 
with immunohistochemical staining demonstrating the presence of PP. Beside these four 
cases, there have been multiple case reports about PPomas, excluded from table 1 because 
either of lacking WDHA syndrome or because no real circumscribed pancreatic tumor 
could be identified [9, 10]. 
As shown in table 1, the normal serum level of VIP and the elevated serum level of PP 
suggest that the symptoms in our patient seem to be derived from the high levels of 
circulating PP. A correlation between the serum PP concentrations and the WDHA 
syndrome could be demonstrated by absence of the syndrome after removal of the tumor 
due to an immediate fall in serum PP. PPomas should be treated as nonfunctioning ETPs. 
Preoperatively US, CT scan or endoscopic ultrasound are the procedures of choice and 
are usually effective, because these tumors are relatively large [11, 12]. Also SRS can be 
performed to differentiate endocrine from nonendocrine pancreatic tumors. Recognition 
of ETPs is imperative because of their good resectability and excellent long-term survival 
compared to that of ductal pancreatic carcinoma [13, 14]. The major goal is a potentially  
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curative resection with no tumor tissue left behind. This may require partial 
pancreatoduodenectomy in large tumors with local signs of malignancy or enucleation 
like in the present case. 
Some years ago, Jensen described eight different neoplastic disorders that can cause 
chronic diarrhea [15]. This list included gastrinomas, VIPomas, glucagonomas, 
somatostatinomas, and calcitonin-producing tumors. The present case suggests that, 
although rare, PPomas have to be added to this list. 
 
 
 
Table 1. Pure PPomas with WDHA syndrome 
Author, 
reference 
Year Localization  of 
tumor 
PP serum levels 
preoperatively 
VIP serum levels 
preoperatively 
Operation  PP serum levels 
postoperatively 
Follow-up 
Larsson [5]  1976  pancreatic head  47 nmol/l  normal  yes  5 nmol/l  DOD 
Hayes [6]  1980  NA  NA  NA  NA  NA  NA 
Strodel [7]  1984  pancreatic body  3,5100 pg/ml  NA  yes  228 pg/ml  NED 
postoperatively
Mortenson 
[8] 
2002 pancreatic  tail  elevated  normal  yes  NA  NA 
Present 
study 
2007  pancreatic head  4,370 pg/ml  normal  yes  60 pg/ml  NED after 
3 years 
NED = No evidence of disease; DOD = death of disease; PP = pancreatic polypeptide; VIP = vasoactive 
intestinal polypeptide; NA = not available. 
 
 
 
 
Fig. 1. a CT imaging of the abdomen showing a pancreatic head tumor 4.2 × 3.3 cm in size. 
b Intraoperative ultrasound showing a hypoechogenic tumor. 
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Fig. 2. a Intraoperative situs showing the tumor shortly before its enucleation. The tumor is flanked by 
four holding sutures and enucleated from the surrounding tissue. b Tumor specimen showing a tumor 
3 cm in diameter. c, d Immunohistochemistry staining revealing strong positive staining for 
chromogranin A (c) and PP (d). 
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